Profile data is unavailable for this security.
About the company
KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.
- Revenue in JPY (TTM)87.25bn
- Net income in JPY18.24bn
- Incorporated1948
- Employees1.14k
- LocationKaken Pharmaceutical Co Ltd20F, Bunkyo Green Court Center Office2-28-8, HonkomagomeBUNKYO-KU 113-8650JapanJPN
- Phone+81 359775001
- Fax+81 359775131
- Websitehttps://www.kaken.co.jp/
More ▼
Mergers & acquisitions
Acquired company | 4521:TYO since announced | Transaction value |
---|---|---|
Eisai Co Ltd-Merislon & Myonal | 28.28% | 25.10m |
Data delayed at least 20 minutes, as of Nov 25 2024 06:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zeria Pharmaceutical Co Ltd | 81.47bn | 8.40bn | 119.20bn | 1.78k | 11.78 | 1.12 | 7.31 | 1.46 | 190.47 | 190.47 | 1,848.22 | 2,002.47 | 0.5316 | 1.50 | 3.60 | 45,846,530.00 | 5.49 | 3.89 | 8.46 | 6.28 | 72.99 | 71.93 | 10.33 | 7.57 | 0.9178 | -- | 0.3244 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
Mochida Pharmaceutical Co Ltd | 104.51bn | 4.53bn | 124.21bn | 1.52k | 25.95 | 0.9103 | 16.72 | 1.19 | 127.75 | 127.75 | 2,945.16 | 3,641.81 | 0.6639 | 1.80 | 3.42 | 68,662,940.00 | 2.88 | 4.37 | 3.41 | 5.31 | 49.61 | 52.47 | 4.34 | 6.71 | 3.50 | -- | 0.00 | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
Torii Pharmaceutical Co Ltd | 58.84bn | 5.28bn | 137.09bn | 583.00 | 25.36 | 1.11 | 24.06 | 2.33 | 187.71 | 187.71 | 2,093.33 | 4,271.84 | 0.4411 | 2.74 | 2.30 | 100,924,500.00 | 3.96 | 6.52 | 4.39 | 7.35 | 44.46 | 49.55 | 8.97 | 17.98 | 5.19 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
Towa Pharmaceutical Co Ltd | 243.94bn | 15.78bn | 145.28bn | 4.59k | 8.80 | 0.8725 | 4.20 | 0.5955 | 320.50 | 320.50 | 4,956.02 | 3,232.16 | 0.5838 | 1.52 | 3.93 | 53,169,570.00 | 3.78 | 4.21 | 4.56 | 5.63 | 36.10 | 39.23 | 6.47 | 7.23 | 1.63 | -- | 0.581 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
Kissei Pharmaceutical Co Ltd | 81.07bn | 10.73bn | 180.23bn | 1.78k | 15.12 | 0.7356 | 11.80 | 2.22 | 241.71 | 241.71 | 1,825.83 | 4,969.03 | 0.3294 | 1.60 | 2.98 | 45,568,860.00 | 4.38 | 3.61 | 4.75 | 3.90 | 49.88 | 49.47 | 13.31 | 12.69 | 4.15 | -- | 0.0057 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
KAKEN PHARMACEUTICAL CO., LTD. | 87.25bn | 18.24bn | 204.94bn | 1.14k | 9.26 | 1.09 | 9.81 | 2.35 | 481.71 | 481.71 | 2,303.80 | 4,076.80 | 0.4864 | 1.98 | 3.88 | 76,867,840.00 | 10.17 | 6.83 | 11.66 | 7.87 | 60.66 | 54.78 | 20.91 | 14.48 | 4.47 | -- | 0.0243 | 51.25 | -1.29 | -5.21 | 47.52 | -14.70 | 0.3639 | 0.00 |
Sumitomo Pharma Co Ltd | 342.67bn | -279.46bn | 242.32bn | 4.98k | -- | 2.12 | -- | 0.7072 | -703.41 | -703.41 | 862.50 | 287.37 | 0.3517 | 1.30 | 4.28 | 68,808,230.00 | -28.68 | -5.07 | -51.21 | -7.73 | 59.56 | 69.99 | -81.54 | -12.28 | 0.424 | -12.10 | 0.7732 | -- | -43.38 | -7.29 | -322.71 | -- | 4.02 | -- |
Sawai Group Holdings Co Ltd | 177.34bn | 16.55bn | 259.26bn | 3.48k | 15.58 | 1.21 | 9.13 | 1.46 | 126.61 | 184.41 | 1,357.79 | 1,623.19 | 0.4658 | 1.12 | 2.83 | 50,929,920.00 | 3.17 | 0.7104 | 4.24 | 0.9705 | 30.73 | 35.08 | 6.80 | 1.47 | 1.39 | 38.13 | 0.3169 | 88.13 | 8.04 | -0.8249 | 46.82 | -2.33 | 18.15 | 0.00 |
Nippon Shinyaku Co., Ltd. | 154.27bn | 26.05bn | 294.07bn | 2.21k | 10.82 | 1.20 | 9.31 | 1.91 | 386.74 | 386.74 | 2,290.53 | 3,486.81 | 0.5956 | 1.29 | 3.36 | 69,711,700.00 | 10.06 | 10.45 | 11.39 | 12.31 | 67.69 | 61.27 | 16.89 | 16.47 | 4.22 | -- | 0.0107 | 32.62 | 2.83 | 5.26 | 13.32 | 9.66 | 45.93 | 12.12 |
Data as of Nov 25 2024. Currency figures normalised to Kaken Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
Holder | Shares | % Held |
---|---|---|
Silchester International Investors LLPas of 26 Mar 2024 | 2.22m | 4.82% |
The Vanguard Group, Inc.as of 06 Nov 2024 | 1.16m | 2.52% |
Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 1.08m | 2.36% |
Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 502.10k | 1.09% |
Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 478.10k | 1.04% |
BlackRock Fund Advisorsas of 07 Nov 2024 | 392.70k | 0.86% |
Brandes Investment Partners LPas of 20 Nov 2024 | 386.00k | 0.84% |
Asset Management One Co., Ltd.as of 07 Nov 2024 | 292.80k | 0.64% |
Norges Bank Investment Managementas of 30 Jun 2024 | 291.91k | 0.64% |
Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 2024 | 276.30k | 0.60% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.